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ABSTRACT
Background: Inflammation and oxidative stress caused by cigarette smoking contribute 
to chronic obstructive pulmonary disease (COPD). Smoking and oxidative stress lead to 
accelerated formation and accumulation of advanced glycation end products (AGEs), causing 
local tissue damage either directly or by binding the receptor for AGEs (RAGE). This study 
assessed the association of AGEs or RAGE in plasma, sputum, bronchial biopsies and skin with 
COPD and lung function, and their variance between these body compartments.
Methods: Healthy smoking and never-smoking controls (n=191, age 18-40 years) and COPD 
patients (n=97, GOLD stage I-IV) were included. Autofluorescence (SAF) was measured in 
the skin, AGEs (pentosidine, CML and CEL) and sRAGE in blood and sputum by ELISA, and in 
bronchial biopsies by immunohistochemistry.
Results: Higher SAF and lower sRAGE levels associated with COPD and lower lung function 
(p <0.001; adjusting for relevant covariates). Lower plasma sRAGE levels significantly and 
independently predicted higher SAF values (p<0.001). 
Conclusion: In COPD, AGEs accumulate differentially in body compartments, i.e. they 
accumulate  in the skin, but not in plasma, sputum and bronchial biopsies. The association 
between lower sRAGE and higher SAF levels supports the hypothesis that the protective 
mechanism of sRAGE as a decoy-receptor is impaired in COPD.




Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation, 
accompanied by persistent inflammation of the airways, mainly caused by cigarette smoking. 
Both smoking and inflammation are associated with oxidative stress leading to accelerated 
formation and accumulation of advanced glycation end products (AGEs) (1,2).
 AGEs are a heterogeneous and complex group of compounds that are irreversibly 
formed by non-enzymatic glycation and oxidation of proteins and lipids (3). They accumulate 
in tissues with ageing, and under oxidative stress and inflammatory conditions their formation 
and accumulation increases. Therefore, accumulation of AGEs can be used as a read-out system 
for exposure to oxidative stress during life. This is particularly true in tissues with slow turnover, 
more than in tissues or products from tissues with rapid turnover. The best known AGEs are Nε-
(carboxymethyl)lysine (CML), Nε-(carboxyethyl)lysine (CEL) and pentosidine. AGEs cause local 
tissue damage by affecting protein structure, by formation of crosslinks between molecules, 
or by binding the receptor for AGE (RAGE) (4,5). RAGE is a member of the immunoglobulin 
superfamily and is a pattern-recognition receptor on cell surfaces. Ligation of RAGE triggers 
inflammatory responses, induces oxidative stress, and in turn causes RAGE over-expression. 
This finally leads to increased tissue remodeling (5). Interestingly, expression of RAGE in the 
lung has shown to be relatively high when compared with other tissues (6).
 A few studies have indicated that AGEs are involved in the pathology of COPD. One 
study showed increased accumulation of AGEs in lung parenchyma and small airways of 
COPD patients (7). We and others found increased AGEs accumulation in the skin of COPD 
patients compared to healthy smoking and never-smoking controls (8,9). Furthermore, 
plasma CML levels in COPD are elevated compared to non-COPD controls (9), suggesting a 
systemic component that may contribute to AGEs accumulation outside the lung, and to extra-
pulmonary manifestations of COPD. Regarding RAGE, it has been shown that immunostaining 
of the receptor is increased in bronchial biopsies and lung parenchyma of COPD patients 
(7,10). Importantly, RAGE also exists as soluble form (sRAGE). It has been postulated that sRAGE 
can act as a decoy receptor by clearance of circulating AGEs, in this way preventing ligation 
of membrane bound RAGE. This possible ‘protective’ mechanism may be reduced in COPD, as 
levels of sRAGE have found to be lower in COPD patients than in non-COPD controls (11-15).
 Taken together, studies so far suggested that the AGE-RAGE axis is involved in the 
pathology of COPD. In the current study we evaluated both AGEs and (s)RAGE levels in plasma, 
sputum, bronchial biopsies and the skin in the same study subjects. Young (18-40) and old 
(40-75) smokers and never-smokers, and mild-to-very severe COPD patients were included. We 
studied whether the expression of AGEs or RAGE in the different tissues was associated with 
COPD and lung function values, and whether the expression of AGEs and/or RAGE levels in 
different tissues were associated. 
METHODS
Subjects
Data were collected from two studies performed in Groningen and Utrecht, the Netherlands 
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(Clinicaltrials.gov: NCT00807469 and NCT00848406 (A multi-center study (16)) and 
NCT00848406). All participating subjects gave peripheral blood and performed an AGE-reader 
measurement, while a subgroup of subjects underwent sputum induction and bronchoscopy 
with collection of bronchial biopsies. All measurements were obtained by using standardized 
protocols. The studies were approved by the medical ethics committees of University Medical 
Centers Groningen (UMCG) and Utrecht (UMCU), the Netherlands. 
 Mild to very severe COPD patients (40-75 years, >10 packyears), as classified by 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) (17) were recruited from 
outpatient clinics of UMCG and UMCU. Old (40-75 years) and young (18-40 years) healthy 
smokers and healthy never-smokers were recruited by advertisements. Old smokers had a 
smoking history >10 packyears and young smokers >0.5 packyears. All never-smoking subjects 
had smoked <0.5 packyears. Healthy participants had no history of pulmonary diseases and 
showed normal spirometry. Exclusion criteria for all groups were alpha-1 antitrypsin deficiency 
and a doctors’ diagnosis of asthma. 
Determination of AGEs and RAGE in peripheral blood samples and sputum
Blood was collected in tubes containing EDTA and was immediately placed on ice. After 
centrifugation (twice at 2000 rcfmax, 10 min, 4°C) samples were stored at -80°C until analysis. 
Sputum induction was performed according standard protocols (detailed methods in online 
supplement). Sputum samples were centrifuged (10 min, 450g, 4°C) and the supernatant was 
stored at -80°C until analysis. 
In plasma and sputum samples, ELISA was performed to determine levels of total 
sRAGE (cleaved and secreted forms) (RAGE DuoSet; R&D Systems, Minneapolis, MN, USA), CEL 
(Cell Biolabs Inc. San Diego, CA, USA), CML (Cell Biolabs Inc. San Diego, CA, USA) and Pentosidine 
(Uscn Life Science Inc., Wuhan, China), all according to the manufacturer’s instructions.
Determination of AGEs and RAGE in bronchial biopsies
Bronchial biopsies were taken from subsegmental carinae of the right lower lobe. Biopsies 
were fixed in 4% neutral buffered formalin, processed and embedded in paraffin and cut in 
3 µm sections. After antigen retrieval, sections were incubated with the primary monoclonal 
antibody against AGEs (anti-AGEs (clone 6D12), 1:750, Cosmo Bio Co, Ltd, Tokyo, Japan) or RAGE 
(anti-RAGE (ab7764), 1:1500, Abcam, Cambridge, UK). Immunohistochemical stainings were 
performed using the DAKO autostainer (DAKO, Glostrup, Denmark). Quantification of both 
stainings was performed by calculating the percentage positive and strong positive pixels of 
the total amount of pixels in whole biopsies, using ImageScope (Aperio Technologies, version 
11.2.0.780). Detailed immunohistochemistry and quantification procedures are presented in 
the online supplement.
Measurement of AGEs using Skin autofluorescence in the skin
Skin autofluorescence (SAF) was assessed non-invasively by the AGE-ReaderTM (DiagnOptics 
B.V., Groningen, The Netherlands) (18). Technical details of this device have been extensively 
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described elsewhere and briefly in the online supplement. (19). In short, the volar surface of 
subject’s forearm was positioned on top of the device and three consecutive measurements 
were performed for each subject. In all analyses, SAF was expressed as the mean of these three 
measurements in arbitrary units (AU).
Statistical analysis
Differences in expression of AGEs and RAGE between groups were analyzed by Kruskal-Wallis 
test, followed by Mann-Whitney U tests if significant. Associations with COPD were examined 
by multiple regression analyses with AGEs or RAGE expression as dependent variables, and 
COPD or lung function values as predictor variables. Associations of AGEs and RAGE between 
different compartments were additionally analyzed by multiple regression models. All models 
were adjusted for co-variates that associate with AGEs formation, including age, gender, 
packyears, BMI, LDL cholesterol, and triglycerides. Benjamini Hochberg corrections were 
applied to correct for multiple testing (20). Regression models were considered valid if the 
residuals were normally distributed. Statistical analyses were performed using the statistical 
program IBM SPSS Statistics version 20. 
RESUlTS
Subject characteristics
In total, 108 young controls (including 36 never-smokers and 72 smokers), 83 old controls 
(including 28 never-smokers and 55 smokers) and 97 COPD patients (32 GOLD I, 25 GOLD II, 24 
GOLD III, 16 GOLD IV) were included. Group characteristics are presented in Table 1. 
Table 1. Group characteristics
  Young healthy Old healthy COPD
  n=108 n=83 n=97
Age, years 25 (66) 54 (8.9) 62 (7.6)
Males, n (%) 54 (50) 60 (72) 68 (70)
Current smokers, n (%) 72 (67) 54 (65) 51 (53)
Cigarettes per day 9 (6.8) 16 (7.1) 11 (7.9)
Packyears 3.1 (4.8) 20 (18.0) 38 (16.8)
BMI, kg/m2 23.0 (2.8) 25.3 (3.6) 25.5 (4.7)
FEV1,%pred 108 (9.5) 110 (13.5) 62 (27)
FEV1/FVC (%) 85 (5.7) 79 (5.0) 48 (14)
RV/TLC (%) 23.3 (5.1) 31.1 (4.4) 45.8 (11.3)
FEF25-75, %pred 101 (18.7) 100 (30.4) 24 (17)
TLCOc/VA, %pred 97 (13.3) 98 (12.6) 67 (24)
LDL cholesterol, mmol/L 2.6 (0.8) 3.6 (1.0 3.4 (1.0)
Triglycerides, mmol/L 1.0 (0.8) 1.4 (1.0) 1.2 (0.7)
Fasting glucose, mmol/L 5.2 (1.3) 5.6 (0.7) 5.8 (0.7)
Creatinine, µmol/L 73.7 (10.9) 80.2 (14.5) 82.7 (14.8)
Data are presented as mean (sd) unless otherwise stated. n=number, BMI=body mass index, FEV1=forced 
expiratory volume in one second, FVC=forced expiratory volume, RV=residual volume, TLC=total lung capacity, 
FEF=forced expiratory flow, TLCOc/VA=transfer coefficient for carbon monoxide, LDL=low density lipoprotein.
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AGEs 
Expression of AGEs in plasma, sputum, bronchial biopsies and the skin is presented in Figure 
1 and Table 2. 
In plasma (Figure 1A), CEL levels were significantly higher in young healthy subjects 
than in old healthy subjects and COPD patients. Furthermore, plasma CML levels were 
significantly higher in COPD patients than young and old subjects, and higher in the young 
group than in the old healthy group. Plasma pentosidine levels did not differ between groups. 
In sputum (Figure 1B), CEL and CML levels did not differ between groups, whereas pentosidine 
levels were too low to be detected; only 11 sputum supernatant samples of the total 182 
samples were above the detection limit of 1.45 ng/ml. AGEs immunopositivity In whole 
bronchial biopsies, was not differently expressed between groups, (Figure 1C), neither were 
quantitative analyses in the intact and basal epithelium, smooth muscle and connective tissue 
(Figure 1, online supplement). However, accumulation of AGEs in the skin was significantly 
different between all groups, with highest SAF values in COPD patients and lowest values in 
the young group (Figure 1D) 
In all measurements, levels of AGEs did not differ between the COPD severities (GOLD 
I-IV, Table 1, online supplement). Additionally, AGEs levels are presented separately for healthy 
never-smokers and smokers (Table 1, online supplement).
Table 2. AGE and RAGE expression in young and old subjects, and COPD patients
  Young healthy Old healthy COPD GOlD I-IV Kruskal-Wallis
  <40 years >40 years >40 years p-value
Plasma n=105 n=82 n=95  
CEL, µg/ml 10.2 (7.4-15.4) 7.0 (4.8-10.6) § 6.8 (5.1-9.4) § 0.000*
CML, µg/ml 10.5 (0.0-29.5) 9.2 (0.0-13.5) § 12.5 (0.0-21.6) §‡ 0.042*
Pentosidine, ng/ml 36.8 (25.3-53.1) 39.9 (30.1-52.0) 46.1 (31.8-58.5) 0.181
sRAGE, pg/ml 795 (614-1089) 805 (617-1032) 414 (292-592) §‡ 0.000*
Induced sputum n=97 n=73 n=12  
CEL, µg/ml 5.9 (1.9-8.9) 3.50 (0.0-6.9) 6.0 (2.9-11.0) 0.064
CML, µg/ml 10.6 (0.0-22.7) 10.4 (0.0-23.7) 18.3 (11.2-22.5) 0.409
Pentosidine, ng/ml 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.650
sRAGE, pg/ml 78.1 (0.0-160.2) 114.0 (0.0-240.5) 110.9 (49.7-161.8) 0.117
Bronchial Biopsies n=85 n=68 n=12  
AGEs, positivity (%) 31.1 (20.3-36.9) 25.9 (20.9-35.4) 25.5 (16.9-30.7) 0.418
RAGE, positivity (%) 9.8 (6.5-15.1) 8.2 (5.7-11.8) 8.0 (4.2-11.4) 0.204
Skin n=107 n=83 n=96  
AGE-reader, SAF 1.2 (1.1-1.5) * 1.8 (1.6-2.0) * 2.5 (2.2-2.9) * 0.000*
Data are expressed as medians (IQR). * p<0.05 between all groups, § p<0.05 compared with the young healthy 
group, ‡ compared with the old healthy group. CEL= Nε-(carboxyethyl)lysine, CML= Nε-(carboxymethyl)lysine, 
RAGE= receptor for advanced glycation endproducts, AGEs= advanced glycation endproducts, SAF= skin 
autofluorescence.
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figure 1. AGEs expression in plasma, sputum, bronchial biopsies and the skin
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AGEs levels in A) plasma, B) sputum, C) bronchial biopsies and D) skin (SAF). Horizontal lines represent median 
values with interquartile ranges, * p<0.05 between groups.
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RAGE
Levels of RAGE in plasma, sputum and bronchial biopsies are presented in Figure 2 and Table 2.
In plasma, sRAGE levels were significantly lower in COPD patients than in young and 
old healthy subjects (Figure 2A). In addition, COPD GOLD stage III patients had lower sRAGE 
levels than GOLD stage I patients, and GOLD stage IV patients had lower sRAGE levels than 
GOLD stage I and II (Figure 2A and Table 1 in online supplement). No differences were found 
between young and old healthy subjects. RAGE levels in sputum and RAGE immunopositivity 
in whole sections from bronchial biopsies did not differ between groups (Figure 2B and 2C). 
When studying different parts of the bronchial biopsies (intact and basal epithelium, smooth 
muscle, connective tissue) no  group differences were found (Figure 1, online supplement).
 RAGE levels in healthy never-smokers and smokers are presented in Table 1 in the 
online supplement.
figure 2. RAGE expression in plasma, sputum and bronchial biopsies
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RAGE levels in A) plasma, B) sputum, and C) bronchial biopsies. Horizontal lines represent median values with 
interquartile ranges, * p<0.05 between groups.
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Associations between COPD, lung function and AGEs and RAGE
Table 3(A-B) shows the results of multiple regression analyses with COPD or lung function 
values as predictors of AGEs and RAGE expression in the different compartments.
 In established COPD, a lower FEV1 %predicted, FEV1/FVC, FEF22-75 % predicted, as 
well as a higher RV/TLC were associated with a higher SAF, independently of age, gender, 
number of packyears, BMI, LDL cholesterol and triglycerides (Table 3A). No associations were 
observed between COPD or lung function values on one hand and AGEs in plasma, sputum 
and bronchial biopsies on the other hand.
 Regarding RAGE, both established COPD and impaired lung function values were 
associated with higher levels of soluble RAGE in plasma (Table 3B). No associations were found 
of COPD or lung function values with RAGE levels in sputum and bronchial biopsies.
Associations of AGEs and RAGE expression between different compartments 
Results of multiple regression analyses are presented in Table 4, reflecting associations 
between AGEs and RAGE expression in the different tissues after adjustment for age, gender, 
packyears, BMI, LDL cholesterol and triglycerides. Lower plasma sRAGE levels were significantly 
associated with higher SAF values. Furthermore no significant associations were found.
figure 3. Associations between sRAGE and SAf 




Rho=correlation coefficient, SAF=skin autofluorescence, sRAGE is soluble receptor for advanced glycation 
endproducts. Association after adjustment for age, gender, packyears, BMI, LDL cholesterol and triglycerides was 
in B=0.00, p=<0.01.
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DISCUSSIOn
In this study we investigated a large COPD and a non-COPD control population with respect to 
the accumulation of AGEs and expression of its receptor RAGE in different body compartments 
including plasma, induced sputum, bronchial biopsies and the skin. We performed this study 
in COPD, a chronic disease which for a long time has been associated with chronic oxidative 
stress, the most important accelerator of AGES formation. Our study shows that SAF values 
in the skin were higher in COPD than in young and old non-COPD controls, whereas the 
expression of AGEs in bronchial biopsies was not different between the groups. In addition, 
sRAGE levels in plasma were lower in COPD patients. Of interest, lower sRAGE associated with 
higher SAF, fitting the hypothesis of a ‘protective’ function of sRAGE by acting as a decoy-
receptor preventing accumulation in the skin.
 In COPD, oxidative stress is thought to be continuously increased as a consequence 
of ongoing inflammation (endogeneous component) and chronic smoking (exogeneous 
component). This continuous exposure to oxidative stress, both locally in lung tissue as well 
as systemically in peripheral blood, might lead to increased accumulation of AGEs inside 
and outside the lung. In the current study we demonstrated that AGEs accumulation was 
elevated in the skin of COPD patients, a finding that we and others have observed before (8,9). 
Interestingly, SAF values were comparable between the different severity stages of COPD. 
This suggests that AGEs formation is not increased during disease progression, but may be 
accelerated in the induction phase of COPD. Our data may suggest the following processes: 
AGEs accumulate due to oxidative stress responses to some extent during aging in healthy 
smokers, whereas this is accelerated with chronic smoking in healthy smokers. The highest 
AGEs would be expected in ‘susceptible’ smokers, i.e. subjects who develop COPD. Here, AGEs 
accumulate due to a combination of ageing and disease-related exaggerated response to 
smoking and associated local and systemic oxidative stress.
 In contrast with our findings in the skin, AGEs expression in bronchial biopsies was 
not different between COPD patients and non-COPD controls and did not associate with lung 
function values in the total population. This contradicts a previous study showing higher AGEs 
expression in the lung parenchyma and small airways of COPD patients as compared to non-
COPD controls (7). In an effort to replicate these findings we analyzed immunopositivity of 
our bronchial biopsies in numerous ways, e.g. by quantifying AGEs in different parts of the 
bronchial biopsies and by using different antibodies (against total amount of AGEs, CML and 
pentosidine). However, no differential expressions in COPD patients were observed. There are 
several explanations for our negative finding in bronchial biopsies. First, we collected biopsies 
from the central airways whereas oxidative stress might predominantly exist in the peripheral 
airways, and thereby also AGEs formation. Unfortunately, studies comparing oxidative stress 
in central and peripheral airways are scarce. One study showed that isoprostane levels in 
ELF from the peripheral airways were higher than from the central airways, both in smokers 
with and without airway obstruction (21). We also checked expression of AGEs in peripheral 
lung tissue sections of smokers and non-smokers with and without COPD but did not find 
differences between these (small) groups. Secondly, accumulation of AGEs in the lung might 
be limited because of the relatively high turn-over rate of cells and extracellular matrix 
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(22). For example, the turn-over rate of epithelium from the tracheo-bronchial wall in adult 
rodents is estimated to be more than 100 days (23), in contrast to about 20 years of the dermis 
and an infinite turnover time of the ocular lens, both organs in which AGES are stored (24). 
Finally, a quantification problem may contribute to a lower expression of AGEs in the lungs 
of COPD patients, as extracellular matrix proteins are reduced in the central airways of COPD 
patients (25). Obviously, more research at AGEs accumulation is needed in both the central 
and peripheral airways before definitive conclusions can be drawn regarding our conflicting 
results.
 In plasma, we demonstrated that CML, CEL and pentosidine levels were comparable 
between COPD patients and non-COPD controls, after correction for confounding factors. 
Our results are in line with three previous studies in COPD investigating plasma CML levels 
and showing no differences between COPD and non-COPD controls (12,14,26). In contrast, 
one study showed comparable pentosidine levels as well, but lower CML levels and higher 
CEL levels in COPD patients (9). The latter is surprising since CML and CEL both are formed by 
the same pathway, namely via reactive carbonyl compounds. One explanation might be that 
another technique was used, namely mass spectrometry. One also have to realize that AGEs 
are very volatile, hence measure a ‘snap shot’ in time only and results can be affected by food 
intake and smoking as well (1,27).
 Besides their harmful local effects in tissue, AGEs can interact with RAGE thereby 
triggering intracellular signaling in pro-inflammatory pathways. Two previous studies showed 
that immunostaining of RAGE was increased in bronchial biopsies and in lung parenchyma 
of COPD patients (7,10), but we observed no differences with non-COPD controls in the 
current study. RAGE also exists as a soluble form, generated as a splice variant of the advanced 
glycosylation end product-specific receptor (AGER) gene or by proteolysis of the receptor from 
the cell surface. In line with previous studies (11-15), we demonstrated lower levels of sRAGE 
in plasma of COPD patients and these reduced levels were associated with lower lung function 
values in the total population. Of interest, we demonstrated for the first time that lower sRAGE 
levels were associated with increased SAF values. This finding supports the idea that sRAGE 
acts as a decoy receptor. AGEs binding to sRAGE may lead to clearance of AGEs preventing 
to accumulate in body tissues, a protective mechanism that apparently is impaired in COPD 
patients. There are indications that lower sRAGE levels are genetically determined, as a single 
nucleotide polymorphism (SNP) in the AGER gene associates with lower sRAGE levels (11). In 
this perspective, impaired sRAGE levels might contribute to higher levels of AGEs in tissues 
specifically in COPD. 
 Finally, we assessed levels of AGEs and RAGE in sputum supernatant, which has not 
been studied in COPD before. We hypothesized that AGEs and RAGE levels in sputum might 
reflect expression in the lung. No differential levels of both AGEs and RAGE in induced sputum 
from COPD patients and non-COPD controls were found, nor associations with expression in 
bronchial biopsies. This observation fits with the comparable expression of AGEs and RAGE 
between COPD and healthy individuals as observed in our bronchial biopsies. An explanation 
may be that AGEs are released in more peripheral airways and not captured in sputum, as one 
study in COPD demonstrated that CML was elevated in the epithelial lining fluid (ELF) collected 
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in the peripheral airways, but not in the central airways (28). Since this is the first study of AGEs 
and RAGE in sputum, further research is needed. 
 This study is unique because of its large population of healthy smokers and never-
smokers and a large group of COPD patients of all severities, as well as the availability of different 
tissues from each participant. Unfortunately, only a subgroup of COPD patients performed 
sputum induction and a bronchoscopy which may have affected the statistical power of this 
study. Another limitation is that our study had a cross-sectional design. Longitudinal studies 
are needed to investigate changes in AGEs and RAGE levels in the different tissues over time 
and to further assess the potential contributing role of AGEs and RAGE in the development of 
COPD. 
 To summarize, there is growing evidence in the literature for an AGEs - RAGE 
interaction in the pathology of COPD. Our study contributes to this insight since we show an 
increased AGEs accumulation in the skin of COPD patients compared to non-COPD smokers 
and never-smokers. Moreover, we did not observe differences between COPD and non-COPD 
controls in central bronchial biopsies, indicating that accumulation of AGEs is not similar in 
different body compartments. No further associations were found between AGEs and RAGE in 
the different compartments that were investigated. Interestingly, we demonstrated that lower 
sRAGE levels associate with higher AGE accumulation in the skin. This fits  the hypothesis of a 
‘protective’ function of sRAGE by acting as a decoy-receptor preventing accumulation in the 
skin. 
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Sputum induction was performed according to the method described elsewhere with some 
modifications (1). In short, 4,5% hypertonic saline was nebulized with an ultrasonic nebulizer 
(Ultraneb, DeVillbiss, Somerset, PA, USA). Patients inhaled for three periods of five minutes 
and were encouraged to cough and expectorate sputum after each period. The volume of the 
whole sputum sample was determined and an equal volume of 0.1% dithiothreitol (Sputolysin; 
Calbiochem, La Jolla, CA, USA) was added. The samples were agitated during 15 minutes in 
a shaking water bath for 15 minutes at 37°C to complete homogenization and then filtered 
through a 48 µm nylon gauze. The filtered sample was centrifuged (10 min, 450g, 4°C) and the 
supernatant was stored at -80°C until analysis. 
Bronchial biopsies
After administering of local anaesthesia (lidocain 2-4%), a flexible bronchoscope was introduced 
and bronchial biopsies were taken from subsegmental carinae of the right lower lobe. Biopsies 
were fixed in 4% neutral buffered formalin, processed and embedded in paraffin and cut in 3 
µm sections. Quality of biopsies was verified by hematoxylin and eosin (HE) staining. Sections 
were deparaffinized in xylene (2x10 min), rehydrated in alcohol dilations (2x100%, 2x96%, and 
1x70%), and rinsed in demi-water. For AGEs staining, antigens were retrieved by incubating 
the slides in 0,1M Tris-HCl pH 9.0 buffer at 80°C overnight. For RAGE staining, Citrate 10mM 
pH 6.0 buffer was preheated, slides were placed in a plastic container and were heated in 
microwave for 15 min at 400W. After antigen retrieval the slides were cooled down at room 
temperature (RT) and were washed with PBS. All sections were incubated with 0.3% hydrogen 
peroxide H2O2 (Merck, Germany) in PBS (500µl H2O2 30% in 50ml PBS) for 30 min at RT to block 
endogenous peroxidase activity. After three washes with PBS, sections were incubated with 
the primary monoclonal antibody against AGEs (anti-AGEs (clone 6D12), 1:750, Cosmo Bio 
Co, Ltd, Tokyo, Japan) or RAGE (anti-RAGE (ab7764), 1:1500, Abcam, Cambridge, UK) diluted in 
PBS/1%BSA for 1 hour at RT. For AGEs staining, sections were washed in PBS for three times and 
incubated with the secondary antibody (EnvisionTM Detection Systems Peroxidase (DAKO)) for 
30 min at RT. For RAGE staining, sections were washed in PBS for 3 times and incubated with 
the secondary peroxidase labeled rabbit anti-goat antibody (DAKO, 1:100 diluted in PBS/1% 
BSA + 1%AB serum) for 30 min at RT. After washing with PBS 3x, sections were incubated with 
the tertiary peroxidase labeled goat anti-rabbit antibody (DAKO, 1:100 diluted in PBS/1% BSA + 
1%AB serum) for 30 min at RT. After washing the sections for three times in PBS for three times, 
peroxidase activity was visualised by incubating the slides in DAB (3-3’DiaminoBenzidine) 
together with 50 µl of hydrogen peroxide for 10 min at RT. Sections were rinsed in demi water. 
Finally, the sections were counterstained with haematoxilin for approximately 2 min, rinsed in 
tap water, dehydrated in alcohol (70%, 96% and 100%), dried, and mounted with mounting 
medium and covered with a coverslip. Both immunohistochemical stainings were performed 
using the DAKO autostainer (DAKO, Glostrup, Denmark). Quantification of both stainings was 
performed by calculating the percentage positive and strong positive pixels of the total amount 
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of pixels in whole biopsies, using ImageScope (Aperio Technologies, version 11.2.0.780). 
Skin autofluorescence
SAF was assessed non-invasively by the AGE-ReaderTM (DiagnOptics B.V., Groningen, The 
Netherlands) (2). Technical details of this device have been extensively described elsewhere 
(3). In short, the AGE reader illuminates approximately 1 cm2 of the skin, guarded against 
surrounding light, with an excitation light source between 300 and 420 nm (peak excitation 
flow ~350 nm). Only light from the skin is measured between 300 and 600 nm with a 
spectrometer using a 200-µm glass fiber. SAF was calculated by dividing the average light 
intensity emitted per nm over the 420- to 600-µm range by the average light intensity emitted 
per nm over the 300- to 420-µm range, using the AGE Reader software version 2.2. The volar 
surface of subject’s forearm was positioned on top of the device, taking care to perform the 
measurement at normal skin site, i.e. without visible vessels, scars, or other skin abnormalities. 
SAF was averaged from three consecutive measurements for each subject, measured within a 
time period of approximately 2 minutes. In all analyses, SAF is expressed in arbitrary units (AU).
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Table 1. AGE and RAGE expression in young and old never-smokers and smokers, 
and COPD GOlD stages
A. Young healthy never-smokers and smokers
  Young healthy never-smokers Young healthy smokers
Plasma n=36 n=69
CEL 9.0 (6.7-15.0) 11.4 (8.2-16.2)
CML 10.9 (0.0-25.3) 10.5 (0.0-38.1)
Pentosidine 48.7 (32.6-70.9) 35.3 (18.7-47.8)*
RAGE 878.8 (573.3-1113.5) 777.0 (628.8-1077.1)
Sputum n=34 n=63
CEL 4.0 (0.0-9.5) 6.4 (3.8-8.2)
CML 14.8 (0.0-44.8) 0.0 (0.0-17.6)*
Pentosidine 0.0 (0.0-0.0) 0.0 (0.0-0.0)
RAGE 0.0 (0.0-97.1) 101.3 (0.0-195.1)*
Bronchial biopsies n=32 n=53
AGEs, positivity (%) 31.3 (18.5-37.4) 30.6 (20.7-36.9)
RAGE, positivity (%) 8.8 (6.1-14.8) 10.8 (6.8-15.2)
Skin n=36 n=71
AGE-reader 1.20 (1.04-1.40) 1.3 (1.1-1.5)
CEL= Nε-(carboxyethyl)lysine, CML= Nε-(carboxymethyl)lysine, RAGE= receptor for advanced glycation endproducts, 
AGEs= advanced glycation endproducts, SAF= skin autofluorescence. Values are expressed as median (IQR).
B. Old healthy never-smokers and smokers
  Old healthy never-smokers Old healthy smokers
Plasma n=28 n=54
CEL 5.37 (3.29-8.55) 8.56 (5.06-11.26)*
CML 10.97 (0.00-13.64) 0.00 (0.00-12.00)
Pentosidine 39.53 (28.29-45.51) 41.1 (30.12-66.48)
RAGE 810.8 (672.9-1118.5) 795.6 (609.3-953.3)
Sputum n=23 n=50
CEL 0.00 (0.00-3.23) 6.11 (2.47-8.97)*
CML 10.40 (0.00-23.49) 11.46 (0.00-24.41)
Pentosidine 0.00 (0.00-0.00) 0.00 (0.00-0.00)
RAGE 115.2 (0.0-206.9) 114.0 (0.0-262.2)
Bronchial biopsies n=26 n=42
AGEs, positivity (%) 28.2 (19.1-37.4) 25.4 (21.3-33.7)
RAGE, positivity (%) 6.9 (5.0-10.6) 9.5 (6.3-12.5)
Skin n=28 n=55
AGE-reader 1.774 (1.43-2.00) 1.80 (1.60-2.10)
CEL= Nε-(carboxyethyl)lysine, CML= Nε-(carboxymethyl)lysine, RAGE= receptor for advanced glycation endproducts, 
AGEs= advanced glycation endproducts, SAF= skin autofluorescence. Values are expressed as median (IQR).
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figure 1. Quantitative analyses of AGEs and RAGE expression in bronchial biopsies
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Quantitative analyses of AGEs (left panel) and RAGE (right panel) expression in A) intact epithelium, B) basal 
epithelium, C) smooth muscle, D) connective tissue of bronchial biopsies. Intensity of staining was scored 
by a 4-points scale: 0=negative staining, 1=weak positive, 2=positive, and 3=strong positive. Horizontal bars 
represent median values.
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figure 2. Quantitative analyses of AGEs and RAGE expression in peripheral airways
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Quantitative analyses of AGEs (left panel) and RAGE (right panel) expression in A) epithelium and B) smooth 
muscle of the peripheral airways. Intensity of staining was scored by a 4-points scale: 0=negative staining, 
1=weak positive, 2=positive, and 3=strong positive. Horizontal bars represent median values.
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